2026-07-21T17:17:16Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/231792024-11-28T21:06:43Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Bulilete, Oana author Lorente, Patricia author Leiva Rus, Alfonso author Carandell Jäger, Eugenia author Oliver, Antonio author Rojo, Estrella author Pericas, Pau author Llobera Cànaves, Joan author COVID-19 Primary Care Research Group author 2021-03 Objectives: We aimed to evaluate the accuracy of the Panbio (TM) Ag-RDT at primary health care (PHC) centers and test sites in symptomatic patients and close contacts, using the Reverse-Transcription Polymerase Chain Reaction (RT-PCR) test as the gold standard. Methods: The study was conducted in four PHC centers and two test sites in Mallorca, Spain. Consecutive patients older than 18 years, attending the sites for RT-PCR testing were included. Two nasopharyngeal samples were collected, one for RT-PCR and the other was processed on-site using the Panbio (TM) rapid antigen test kit for SARS-CoV-2. The sensitivity and specificity were calculated using RT-PCR as the reference, and the predictive values using the pretest probability results for each analyzed group. Findings: A total of 1369 participants were included; mean age 42.5 +/- 14.9 years and 54.3% women. The overall prevalence was 10.2%. Most participants (70.6%) presented within 5 days of the onset of symptoms. The overall sensitivity was of 71.4% (95% CI: 63.1%, 78.7%), the specificity of 99.8% (95% CI: 99.4%, 99.9%), the positive predictive value of 98.0% (95% CI: 93.0%, 99.7%) and a negative predictive value of 96.8% (95% CI: 95.7%, 97.7%). The sensitivity was higher in symptomatic patients, in those arriving within 5 days since symptom onset and in those with high viral load. Interpretation: Ag-RDT had relatively good performance characteristics in suspected symptomatic patients within five days since the onset of symptoms. However, our data do not support the sole use of Panbio (TM) Ag-RDT in asymptomatic individuals. Funding: None (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. Bulilete O, Lorente P, Leiva A, Carandell E, Oliver A, Rojo E, et al. Panbio (TM) rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care. J Infect. 2021 Mar;82(3):391-8. 10.1016/j.jinf.2021.02.014 1532-2742 0163-4453 Journal of Infection https://hdl.handle.net/20.500.13003/19736 33592253 L2011072875 2-s2.0-85101139146 https://hdl.handle.net/20.500.12105/23179 630188200044 COVID-19 Rapid antigen test Sar-CoV-2 Primary care Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care